Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC

Journal of Controlled Release

Volumn 131, Issue 2, 2008, Pages 86-93

  Hui, Xiaoli ^a   Han, Yu ^a   Liang, Shuhui ^a   Liu, Zhiguo ^a   Liu, Jingtao ^b   Hong, Liu ^a   Zhao, Lina ^a   He, Li ^a   Cao, Shanshan ^a   Chen, Bei ^a   Yan, Kun ^a   Jin, Bin ^a   Chai, Na ^a   Wang, Jing ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b No 451 Hospital of Chinese PLA   (China)

Author keywords

Angiogenesis; Gastric cancer; HUVEC; Phage displayed peptide; Tumor targeting

Indexed keywords

AMINES; PAINTING; TUMORS;

ANGIOGENESIS; CYTOTOXIC AGENTS; GASTRIC CANCER; GASTRIC CANCERS; HUVEC; IMMUNOHISTOCHEMICAL ANALYSIS; IN-VITRO; NUDE MICE; PHAGE DISPLAY TECHNOLOGY; PHAGE DISPLAYED PEPTIDE; TUMOR TARGETING; VASCULATURE;

ENDOTHELIAL CELLS;

PROTEIN GX 1; TECHNETIUM 99M; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMAGING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RADIOCARDIOGRAPHY; STOMACH CANCER; TUMOR VASCULARIZATION; UMBILICAL VEIN; XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PROTEIN BINDING; STOMACH NEOPLASMS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 53049090812     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.024     Document Type: Article

References (52)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (2002) 15-18
4. Hajitou A., Pasqualini R., and Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 16 (2006) 80-88
5. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
6. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 63 (1993) 181-196
7. Kessler T., Bieker R., Padró T., Schwöppe C., Persigehl T., Bremer C., Kreuter M., Berdel W.E., and Mesters R.M. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin. Cancer Res. 11 (2005) 6317-6324
8. Hotz H.G., Gill P.S., Masood R., Hotz B., Buhr H.J., Foitzik T., Hines O.J., and Reber H.A. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J. Gastrointest. Surg. 6 (2002) 159-166
9. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., and Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18 (2000) 1185-1190
10. Kumar C.C., Malkowski M., Yin Z., Tanghetti E., Yaremko B., Nechuta T., Varner J., Liu M., Smith E.M., Neustadt B., Presta M., and Amrstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 61 (2001) 2232-2238
11. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
12. Vogelzang N.J. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J. Clin. Oncol. 24 (2006) 1-3
13. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., and Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
14. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 (2006) 1171-1175
15. Ruoslahti E., and Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18 (2000) 813-827
16. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. Trans. 32 (2004) 397-402
17. Rafii S., Avecilla S.T., and Jin D.K. Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell 4 (2003) 331-333
18. Thorpe P.E., and Ran S. Mapping zip codes in human vasculature. Pharmacogenomics J. 2 (2002) 205-206
19. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., and Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102 (1998) 430-437
20. Kolonin M.G., Pasqualini R., and Arap W. Molecular addresses in blood vessels as targets for therapy. Curr. Opin. Chem. Biol. 5 (2001) 308-313
21. Drevs J., and Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J. Intern. Med. 260 (2006) 517-529
22. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov. Today 7 (2002) 1138-1143
23. Pasqualini R., and Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996) 364-366
24. Trepel M., Arap W., and Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol. 6 (2002) 399-404
25. Kolonin M.G., Sun J., Do K.A., Vidal C.I., Ji Y., Baggerly K.A., Pasqualini R., and Arap W. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J. 20 (2006) 979-981
26. Zurita A.J., Arap W., and Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J. Control. Release 91 (2003) 183-186
27. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
28. Li X.B., Schluesener H.J., and Xu S.Q. Molecular addresses of tumors: selection by in vivo phage display. Arch. Immunol. Ther. Exp. (Warsz). 54 (2006) 177-181
29. Zhang X., Xiong Z., Wu Y., Cai W., Tseng J.R., Gambhir S.S., and Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J. Nucl. Med. 47 (2005) 113-121
30. Zhang C., Jugold M., Woenne E.C., Lammers T., Morgenstern B., Mueller M.M., Zentgraf H., Bock M., Eisenhut M., Semmler W., and Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer. Res. 67 (2007) 1555-1562
31. Sakamoto K., Ito Y., Mori T., and Sugimura K. Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes. J. Biol. Chem. 281 (2006) 24472-24478
32. Lisman T., Moschatsis S., Adelmeijer J., Nieuwenhuis H.K., and De Groot P.G. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 101 (2003) 1864-1870
33. Frochot C., Di Stasio B., Vanderesse R., Belgy M.J., Dodeller M., Guillemin F., Viriot M.L., and Barberi-Heyob M. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg. Chem. 35 (2007) 205-220
34. Curnis F., Gasparri A., Sacchi A., Cattaneo A., Magni F., and Corti A. Targeted delivery of IFN gamma to tumor vessels uncouples antitumor from counter regulatory mechanisms. Cancer Res. 65 (2005) 2906-2913
35. Curnis F., Gasparri A., Sacchi A., Longhi R., and Corti A. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 64 (2004) 565-571
36. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., Gambhir S.S., and Chen X. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46 (2005) 1707-1718
37. Miyoshi T., Hirohata S., Ogawa H., Doi M., Obika M., Yonezawa T., Sado Y., Kusachi S., Kyo S., Kondo S., Shiratori Y., Hudson B.G., and Ninomiya Y. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice. FASEB J. 20 (2006) 1904-1906
38. Marchiò S., Lahdenranta J., Schlingemann R.O., Valdembri D., Wesseling P., Arap M.A., Hajitou A., Ozawa M.G., Trepel M., Giordano R.J., Nanus D.M., Dijkman H.B., Oosterwijk E., Sidman R.L., Cooper M.D., Bussolino F., Pasqualini R., and Arap W. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell. 2 (2004) 151-162
39. Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O.P., Heikkilä P., Kantor C., Gahmberg C.G., Salo T., Konttinen Y.T., Sorsa T., Ruoslahti E., and Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 8 (1999) 768-774
40. Vidal C.I., Mintz P.J., Lu K., Ellis L.M., Manenti L., Giavazzi R., Gershenson D.M., Broaddus R., Liu J., Arap W., and Pasqualini R. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 55 (2004) 8859-8867
41. Zhi M., Wu K.C., Dong L., Hao Z.M., Deng T.Z., Hong L., Liang S.H., Zhao P.T., Qiao T.D., Wang Y., Xu X., and Fan DM. Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biol. Ther. 3 (2004) 1232-1235
42. Liang S., Lin T., Ding J., Pan Y., Dang D., Guo C., Zhi M., Zhao P., Sun L., Hong L., Shi Y., Yao L., Liu J., Wu K., and Fan D. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J. Mol. Med. 84 (2006) 764-773
43. Hong L., Han Y., Shi R., Shao X., Sun L., Zhang Y., Huang D., Chen Z., Zhang G., Liang J., Hu S., and Fan D. ZNRD1 gene suppresses cell proliferation through cell cycle arrest in G1 Phase. Cancer Biol. Ther. 4 (2005) 60-64
44. Khodarev N.N., Yu J., Labay E., Darga T., Brown C.K., Mauceri H.J., Yassari R., Gupta N., and Weichselbaum R.R. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J. Cell Sci. 116 (2003) 1013-1022
45. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 56 (1999) 794-814
46. Eliceiri B.P., and Cheresh D.A. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103 (1999) 1227-1230
47. Chen X., Liu S., Hou Y., Tohme M., Park R., Bading J.R., and Conti P.S. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6 (2004) 350-359
48. Li Z.B., Cai W., Cao Q., Chen K., Wu Z., He L., and Chen X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med. 48 (2007) 1162-1171
49. Lammers T., Kühnlein R., Kissel M., Subr V., Etrych T., Pola R., Pechar M., Ulbrich K., Storm G., Huber P., and Peschke P. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J. Control. Release 110 (2005) 103-118
50. Mitra A., Mulholland J., Nan A., McNeill E., Ghandehari H., and Line B.R. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J. Control. Release 102 (2005) 191-201
51. Mitra A., Coleman T., Borgman M., Nan A., Ghandehari H., and Line B.R. Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. J. Control. Release 114 (2006) 175-183
52. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol. Pharmacol. 3 (2006) 472-487